Compare Biogen Inc (BIIB) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs SiTime Corporation — how do they compare? Biogen Inc trades at $208.69 (market cap $30.13B), while SiTime Corporation trades at $690.43 (market cap $20.05B). The key difference: Biogen Inc is the larger of the two by market cap, and Biogen Inc is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| BIIB | SITM | |
|---|---|---|
Market Cap | $30.13B | $20.05B |
Sector | Health | Technology |
52-Week High | $216.63 | $901.60 |
52-Week Low | $128.93 | $212.77 |
Enterprise Value | $37.20B | $19.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
SITM trades at $700.42, up 1.52% today, with a bullish technical outlook and strong analyst consensus. Recent Q2 2026 earnings beat estimates with EPS of $2.34 versus $1.95 expected, driven by 127% revenue growth from AI infrastructure demand. The stock shows robust institutional interest and positive media coverage highlighting AI timing growth.
Outlook is positive with a consensus price target of $870, but risks include high valuation multiples (P/E 1,111.15, P/S 38.1) and integration challenges from the Renesas acquisition. Earnings momentum and AI exposure support upside, yet execution and premium pricing warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
